Article Versions Notes

Fabbi M, Costa D, Russo D, Arenare L, Gaggero G, Signoriello S, Scambia G, Pisano C, Colombo N, Losito NS, et al. Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab. Diagnostics. 2022; 12(9):2118. https://doi.org/10.3390/diagnostics12092118

Fabbi, Marina, Delfina Costa, Daniela Russo, Laura Arenare, Gabriele Gaggero, Simona Signoriello, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Nunzia Simona Losito, and et al. 2022. "Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab" Diagnostics 12, no. 9: 2118. https://doi.org/10.3390/diagnostics12092118

Fabbi, M., Costa, D., Russo, D., Arenare, L., Gaggero, G., Signoriello, S., Scambia, G., Pisano, C., Colombo, N., Losito, N. S., Filaci, G., Spina, A., Califano, D., Scognamiglio, G., Gadducci, A., Mezzanzanica, D., Bagnoli, M., Ferrini, S., Canzonieri, V., ... Pignata, S. (2022). Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab. Diagnostics, 12(9), 2118. https://doi.org/10.3390/diagnostics12092118